BridgeBio Pharma (BBIO) AI Stock Analysis

• Market Cap: $12.74B
• Dividend Yield: N/A
• Average Volume (3M): 2.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: 7.62%
• EPS Growth: -55.29%
• Country: US
• Employees: 725
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 191,168,500
• 10 Day Avg. Volume: 2,344,472
• 30 Day Avg. Volume: 2,265,367
• PEG Ratio: 0.35
• Price to Book (P/B): -3.50
• Price to Sales (P/S): 23.01
• P/FCF Ratio: -9.79
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $78.40
• Price Target Upside: 23.72% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 55 Neutral
• Price Target: $68.00 ▲(7.31% Upside)

BridgeBio Pharma's overall stock score is driven by strong earnings call results and technical momentum, offset by financial instability and poor valuation metrics. The company's growth potential is evident, but significant risks remain due to high leverage and cash flow challenges.

Positive Factors

Revenue Growth

The substantial revenue growth indicates strong market acceptance and successful commercialization of products, supporting long-term business expansion.

Pipeline Progress

Advancing multiple late-stage trials enhances future revenue potential and strengthens the company's competitive position in the biotech sector.

Strong Cash Position

A robust cash position provides financial flexibility for strategic investments and R&D, crucial for sustaining long-term growth and innovation.

Negative Factors

Profitability Challenges

Persistent profitability issues can hinder reinvestment and growth, posing a risk to the company's long-term financial health and shareholder value.

High Leverage

Excessive leverage increases financial risk and limits operational flexibility, potentially impacting the company's ability to navigate economic downturns.

Increased Operating Costs

Rising operating costs can pressure margins and reduce profitability, challenging the company's ability to maintain cost efficiency over time.

BridgeBio Pharma Business Overview & Revenue Model

Company Description

BridgeBio Pharma (BBIO) is a biotechnology company focused on developing innovative therapeutics for genetic diseases and cancers. The company operates primarily in the pharmaceutical sector, leveraging advanced genetic insights to identify and develop targeted therapies. BridgeBio specializes in creating treatments that address the underlying genetic causes of diseases, with a robust pipeline of product candidates across various stages of clinical development.

How the Company Makes Money

BridgeBio Pharma generates revenue primarily through the development and commercialization of its therapeutic products. The company earns money through product sales once its therapies receive regulatory approval and are launched in the market. Additionally, BridgeBio may engage in partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales. These strategic alliances can enhance revenue streams and provide necessary funding for ongoing research and development. Furthermore, BridgeBio may also receive grant funding for specific projects, contributing to its overall earnings.

BridgeBio Pharma Financial Statement Overview

Summary

BridgeBio Pharma demonstrates strong revenue growth but faces significant profitability and financial stability challenges. The high gross profit margin is a positive indicator, but negative net income and high leverage pose risks. Cash flow management needs improvement to support sustainable growth.

Income Statement

BridgeBio Pharma shows strong revenue growth with a 44.69% increase in TTM, indicating positive momentum. However, the company faces significant challenges with profitability, as evidenced by negative net profit margins and EBIT margins. The gross profit margin remains high at 96.80%, suggesting efficient cost management at the gross level, but overall profitability is hampered by high operating expenses.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity and a high debt-to-equity ratio of -1.50 in TTM, indicating financial instability. Return on equity is positive at 50.71%, but this is due to the negative equity base. The equity ratio is negative, highlighting potential risks in financial health and leverage.

Cash Flow

Cash flow analysis shows a decline in free cash flow growth by -11.53% in TTM, reflecting cash management challenges. The operating cash flow to net income ratio is negative, indicating cash flow issues relative to earnings. However, the free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	353.78M	221.90M	9.30M	77.65M	69.72M	8.25M
Gross Profit	338.84M	218.02M	6.86M	74.21M	66.60M	8.25M
EBITDA	-677.28M	-436.83M	-565.47M	-397.44M	-533.83M	-467.38M
Net Income	-797.12M	-535.76M	-643.20M	-481.18M	-562.54M	-448.72M
Balance Sheet
Total Assets	998.25M	919.34M	546.38M	623.04M	1.01B	703.59M
Cash, Cash Equivalents and Short-Term Investments	645.94M	681.10M	434.88M	428.27M	787.51M	607.09M
Total Debt	8.72M	1.73B	1.74B	1.72B	1.73B	495.79M
Total Liabilities	2.92B	2.38B	1.89B	1.87B	1.88B	595.70M
Stockholders Equity	-1.92B	-1.46B	-1.35B	-1.25B	-870.41M	57.91M
Cash Flow
Free Cash Flow	-589.12M	-521.66M	-529.03M	-425.81M	-546.18M	-407.23M
Operating Cash Flow	-584.82M	-520.73M	-527.72M	-419.49M	-497.93M	-399.71M
Investing Cash Flow	-13.37M	60.78M	54.03M	453.15M	-200.83M	-52.99M
Financing Cash Flow	835.41M	748.46M	451.54M	-13.13M	736.45M	447.19M

BridgeBio Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 63.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 63.37 is above the 20-day moving average (MA) of 56.81, above the 50-day MA of 53.61, and above the 200-day MA of 42.01, indicating a bullish trend. The MACD of 2.74 indicates Negative momentum. The RSI at 66.43 is Neutral, neither overbought nor oversold. The STOCH value of 80.77 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.

BridgeBio Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	―	$10.48B	18.68	29.00%	―	10.73%	81.66%
BMRN	―	$9.97B	19.45	9.07%	―	12.31%	60.21%
IONS	―	$12.01B	―	-39.99%	―	20.42%	33.94%
MDGL	―	$9.53B	-33.28	-36.30%	―	3421.98%	49.62%
BBIO	―	$12.74B	―	―	―	7.62%	-55.29%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MRNA	―	$10.99B	―	-27.50%	―	-38.95%	51.07%

BridgeBio Pharma Corporate Events

BridgeBio Pharma Reports Strong Q3 2025 Results

BridgeBio Pharma, Inc. is a biopharmaceutical company focused on developing transformative medicines for genetic diseases, leveraging a robust pipeline that spans from early-stage research to advanced clinical trials.

BridgeBio Pharma Reports Positive Phase 3 Study Results

BridgeBio Pharma announced positive results from its Phase 3 CALIBRATE study of encaleret for treating autosomal dominant hypocalcemia type 1 (ADH1) on October 29, 2025. The study met all primary and key secondary endpoints, showing significant improvements in calcium and parathyroid hormone levels compared to conventional therapy. Encaleret was well-tolerated, with plans for a New Drug Application submission in 2026. The results suggest encaleret could become a new standard of care for ADH1, potentially impacting the lives of patients with this genetic condition.

The most recent analyst rating on (BBIO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Pharma Announces Positive Phase 3 Study Results

On October 27, 2025, BridgeBio Pharma announced positive results from its Phase 3 FORTIFY study of BBP-418, a treatment for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The study showed significant improvements in motor and pulmonary functions, with a well-tolerated safety profile, marking a potential breakthrough for a disease with no specific treatments. The company plans to file for FDA approval in the first half of 2026, which could position BBP-418 as the first therapy to alter the course of this debilitating condition.

The most recent analyst rating on (BBIO) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on BridgeBio Pharma stock, see the BBIO Stock Forecast page.

BridgeBio Pharma’s Earnings Call Highlights Strong Growth

BridgeBio Pharma’s latest earnings call reflects a predominantly positive sentiment, highlighting strong performance and significant growth prospects. The company showcased impressive revenue growth driven by the successful launch of Attruby, although challenges such as increased operating expenses and competitive pressures were also acknowledged.

BridgeBio Pharma Reports Strong Q2 2025 Results

BridgeBio Pharma, Inc. is a biopharmaceutical company specializing in the development of transformative medicines for genetic diseases, with a diverse pipeline ranging from early-stage research to advanced clinical trials.